NVIDIA co-founder visits Indiana University to explore AI research partnership
NVIDIA co-founder Chris Malachowsky toured Indiana University's research facilities May 12 and 13, meeting with university leaders and state officials to discuss expanding AI infrastructure and research capacity across Indiana.
Malachowsky leads NVIDIA's 50-state AI compute initiative, a national effort to increase access to AI resources and education. His visit included stops at the Stark Neurosciences Research Institute at the IU School of Medicine, where he met with Gov. Mike Braun, IU Health CEO Dennis Murphy, and executives from BioCrossroads and the Indiana Biosciences Research Institute.
"NVIDIA's mission is to solve the world's hardest problems, and IU is an incredible partner to help us do exactly that," Malachowsky said in a statement.
Indiana's $1 billion biosciences bet
IU has invested more than $800 million in biosciences and AI since 2023. The state committed an additional $1 billion over 10 years to grow life sciences jobs, announced by Gov. Braun in March.
The partnership reflects IU's position at the intersection of AI research, healthcare, and industry. The university manages Big Red 200, a high-performance computing system that supports over 500 AI research projects powered by NVIDIA technology.
IU has published 19,367 papers and filed 190 patents in AI and machine learning across 21 academic disciplines.
Alzheimer's research as a focal point
The Stark Neurosciences Research Institute has received nearly $680 million in research grants since 2016. IU's Alzheimer's work combines basic science, clinical trials, data science, and patient care into a single coordinated effort.
The university manages several major Alzheimer's initiatives: AI4AD, a $17.4 million project that uses machine learning to identify disease patterns in individual patients; MPS-AD, which develops stem-cell models; and MODEL-AD, a consortium creating animal models for late-stage disease. IU also hosts NCRAD, one of the nation's leading Alzheimer's biobanks.
IU's $40 million collaboration with Eli Lilly focuses on Alzheimer's and neurodegenerative disease research. The TREAT-AD drug discovery center is currently validating several promising compounds for further investigation.
Academic-industry initiative drives engagement
The IU Launch Accelerator for Biosciences, or IU LAB, received a $138 million investment from Lilly Endowment to connect the university's $1 billion research enterprise with Indiana's $102 billion life sciences economy.
David Rosenberg, president and CEO of IU LAB, said the NVIDIA visit reflects sustained effort to position the university at the forefront of industry partnerships. "When you've made the strategic investments and have world-leading experts, you can be confident to identify new strategic engagements," he said.
The three-mile corridor anchoring downtown Indianapolis-including IU Indianapolis, the IU School of Medicine, and IU Health's $4.3 billion campus-positions the region as a hub for AI-driven research and development.
For executives evaluating AI strategy and healthcare innovation: AI for Executives & Strategy and AI for Healthcare provide frameworks for understanding how institutions structure AI investments and partnerships.
Your membership also unlocks:
